Original Research

Massive testing in the Galapagos Islands and low positivity rate to control SARS-CoV-2 spread during the first semester of the COVID-19 pandemic: a story of success for Ecuador and South America

AUTHORS

name here
#Alexander Paolo Vallejo-Janeta
1 BSc, Laboratory Technician

name here
#Diana Morales-Jadan
2 MSc, PhD Student ORCID logo

name here
#Alberto Velez
3 MSc, Laboratory Technician

name here
#Patricio Vega-Marino
4 MSc, Laboratory Technician

name here
#Byron Freire-Paspuel
5 MSc, Laboratory Technician ORCID logo

name here
Maria Belen Paredes-Espinosa
6 BSc, Laboratory Technician

name here
Angel S Rodriguez Pazmiño
7 MSc, Laboratory Technician

name here
Bernardo Castro-Rodriguez
8 PhD Student

name here
Paulina Castillo
9 BSc, Laboratory Technician

name here
Carlos Masaquiza
10 BSc, Laboratory Technician

name here
Ismar Rivera-Olivero
11 PhD, Professor

name here
Esteban Ortiz-Prado
12 MD, PhD, Professor ORCID logo

name here
Aquiles Rodrigo Henriquez-Trujillo
13 MD, Professor

name here
Barbara Coronel
14 MD, Clinical Staff

name here
Heberson Galvis
15 MD, Clinical Staff

name here
Tatiana Jaramillo
16 MSc, Lecturer

name here
Tannya Lozada
17 PhD, Dean of Research, UDLA

name here
Marylin Cruz
18 Veterinary Medicine, Director of ABG Galapagos

name here
UDLA COVID-19 Team

name here
Miguel Angel Garcia-Bereguiain
20 PhD, Professor *

#Contributed equally

AFFILIATIONS

1, 8, 11, 12, 13, 20 One Health Research Group, Universidad de Las Américas, Quito, Ecuador

2 One Health Research Group, Universidad de Las Américas, Quito, Ecuador; and UDLA-COVID-19 Team, Universidad de Las Américas, Quito, Ecuador

3, 4, 9, 10, 18 Agencia de Regulación y Control de la Bioseguridad y Cuarentena para Galápagos, Santa Cruz, Islas Galápagos, Ecuador

5, 6, 7, 14, 15, 16 UDLA-COVID-19 Team, Universidad de Las Américas, Quito, Ecuador

17 Dirección General de Investigación, Universidad de Las Américas, Quito, Ecuador

ACCEPTED: 5 May 2023

Miguel Angel Garcia-Bereguiain: Massive testing in the Galapagos Islands to control SARS-CoV-2


early abstract:

Introduction: During the first months of COVID-19 pandemic in Latin America, several countries like Ecuador, Peru or Colombia experienced chaotic scenarios with public health systems collapsed and lack of testing capacity to control the spread of the virus. In main cities like Guayaquil in Ecuador, dramatic situations like body corpses in the streets where internationally broadcasted. However, while COVID-19 pandemic was devastating South America, SARS-CoV-2 transmission was successfully managed at Galapagos Islands due to the implementation of a massive screening strategy combining hospitalized and community dwelling population, and travel restrictions facilitated by its geographical location (972 km far from the Ecuadorian continental territory). For instance, Floreana Island was one of the few locations in the world that remained COVID-19 free during 2020.
Methods: In this study, we retrospectively analyzed the data related to SARS-CoV-2 massive testing campaigns from April to September 2020 in the Galapagos Islands.
Results: Galapagos Islands had the lowest positivity rate in South America (ranging from 4.8 to 6.7%).
Discussion: The low positivity rate in Galapagos Islands was due to the fact that this territory had the highest testing ratio among Ecuadorian provinces (9.87% of the population, meaning 2,480 out of 25,124 inhabitants) during the first wave of COVID-19 pandemic.
Conclusion: This story of success was possible thanks to the inter institutional collaboration between the regional government of Galapagos Islands ("Consejo de Gobierno"), the local authorities ("Gobiernos Autonomos Descentralizados de Santa Cruz, San Cristobal and Isabela"), the regional authorities from Ecuadorian Ministry of Health, the "Agencia de Regulación y Control de la Bioseguridad y Cuarentena para Galápagos" and "Universidad de Las Américas".